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a b  s  t  r a  c t
Introduction: We  present the  protocol  of a large  population-based  case-control  study  of 5 common  tumors
in Spain  (MCC-Spain)  that  evaluates environmental  exposures  and genetic  factors.
Methods:  Between  2008-2013,  10,183  persons  aged  20-85  years  were  enrolled in  23  hospitals  and pri-
mary  care  centres  in 12 Spanish provinces  including 1,115  cases  of a  new  diagnosis  of prostate cancer,
1,750  of breast cancer, 2,171  of colorectal cancer, 492 of gastro-oesophageal  cancer,  554  cases  of  chronic
lymphocytic  leukaemia  (CLL)  and  4,101  population-based  controls matched  by  frequency  to cases  by  age,
sex  and  region of residence.  Participation rates  ranged  from  57% (stomach  cancer)  to  87% (CLL cases)  and
from 30% to  77%  in controls. Participants  completed  a  face-to-face  computerized  interview on sociode-
mographic  factors,  environmental exposures,  occupation, medication,  lifestyle, and  personal  and  family
medical history.  In addition, participants  completed a self-administered  food-frequency  questionnaire
and  telephone  interviews.  Blood samples were  collected  from  76%  of participants  while saliva samples
were  collected  in CLL cases and  participants refusing  blood extractions.  Clinical  information  was  recorded
for  cases  and paraffin  blocks  and/or fresh  tumor samples  are  available  in most collaborating  hospitals.
Genotyping  was  done through  an exome array  enriched with  genetic markers  in specific  pathways. Mul-
tiple  analyses are  planned  to  assess the  association  of environmental, personal and genetic  risk factors
for  each  tumor  and  to  identify  pleiotropic  effects.
Discussion: This  study,  conducted  within  the  Spanish Consortium  for  Biomedical  Research in Epidemiol-
ogy  & Public Health (CIBERESP),  is  a unique  initiative to  evaluate  etiological  factors  for  common  cancers
and will promote  cancer research  and  prevention  in Spain.
© 2014 SESPAS.  Published by  Elsevier  España, S.L.U. All rights  reserved.
Abbreviations: CLL, Chronic Lymphocytic Leukaemia; FFQ, Food Frequency Questionnaire; EBV, Epstein-Barr Virus.
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Estudio  multicaso-control  de  base  poblacional  de  tumores  comunes  en  España
(MCC-Spain):  razón  y diseño  del estudio
r e  s  u  m e  n
Introducción:  Presentamos  el protocolo del  estudio  caso-control de  base poblacional  de  5 tumores
comunes en  España (MCC-Spain)  que evalúa  factores  ambientales  y  genéticos.
Métodos:  Durante  2008-2013, se reclutaron 10.183  sujetos  entre 20-85 años  en  23  hospitales  de  12
provincias españolas,  incluyendo  1.115 casos de  cáncer  de  próstata,  1.750 de  mama, 2.171  colorrectal,
492  gastro-esofágicos,  554  de leucemia linfática  crónica  (LLC)  y  4.101  controles poblacionales  empare-
jados por  frecuencia  por edad,  sexo y  región  de  residencia. Las tasas  de  participación  varían  del 57%
(cáncer  de  estómago)  al  87%  (casos  de  LLC)  y  del  30%  al 77%  en  controles.  Los  participantes respondieron
una  entrevista  personal  informatizada  sobre factores  socio-demográficos,  exposiciones  ambientales,  ocu-
pación,  medicación,  estilos  de  vida,  e  historia  médica  personal  y  familiar. Además, cumplimentaron  un
cuestionario  alimentario y  realizaron  entrevistas  telefónicas. Se  recogió sangre  del  76%  de  los partici-
pantes  y  saliva  para  los casos de  LLC y participantes  que rechazaron la  donación de  sangre.  En  los casos, se
recogió  información  clínica y  se dispone de muestras  de  tumor fresco o parafinado  a través  de  los  bioban-
cos  de los  hospitales.  Se  realizó  el genotipado  con  un  array  de  exoma  suplementado con marcadores  en
pathways específicos.  Se  han planificado  diversos análisis para evaluar la asociación de factores  genéticos,
personales  y  ambientales para cada tumor e  identificar  efectos pleiotrópicos.
Discusión:  Este  estudio, desarrollado  en el Consorcio de  Investigación  Biomédica de  Epidemiología  y
Salud Pública (CIBERESP),  es una  iniciativa única para evaluar  factores etiológicos de  tumores comunes  y
promoverá  la investigación  en  cáncer y  prevención  en  España.
©  2014  SESPAS. Publicado  por  Elsevier España, S.L.U. Todos  los  derechos reservados.
INTRODUCTION
A  population-based multicase-control study (MCC-Spain) was
launched in 2007 by the Consortium for Biomedical Research in Epi-
demiology & Public Health (CIBERESP) to  evaluate the influence of
environmental exposures and their interaction with genetic factors
in three of the most common tumours in Spain (prostate, female
breast, colorectal),1 in  which etiological causes remain largely
unknown. Gastric cancer was also included due to its large geo-
graphical variation within Spain,2 which points to the not well
identified persistent environmental exposure in high risk areas (i.e.
Castilla y León). A fifth neoplasm, chronic lymphocytic leukaemia
(CLL) was included later, as a result of the collaboration with the
International Cancer Genome Consortium (ICGC).
Diet, physical activity, obesity and family history are common
risk factors for the tumours examined3,4. Moreover, environmen-
tal and occupational factors have also been investigated in  relation
to these tumours,5–7 but not in the Spanish population. Regarding
infectious hypothesis, the best established risk factor for stomach
cancer is infection with Helicobacter pylori (H. pylori),  while infec-
tious mononucleosis and high levels of Epstein-Barr Virus (EBV)
antibodies have been associated with CLL.8 Non-steroidal anti-
inflammatory drugs (NSAIDs) and statins may be protective for
several of the included tumours. Genome Wide Association Stud-
ies (GWAS) have identified numerous low penetrance variants for
colorectal, breast, and prostate cancer and CLL. 9–12 However, in
spite of all the research conducted so far, the causes of this group
of tumours are not well understood.
The aim of this study is to assess the association between
environmental exposures and individual factors, including genetic
susceptibility, and the occurrence of these cancers in  Spain. In
summary, MCC-Spain intends to  explore and combine different
approaches in order to identify new risk factors of to provide
new data that might help to prevent their occurrence in the
future. The specific objectives of the study are related to:  a)
environmental exposures, including drinking water contaminants,
heavy metals and endocrine disruptors exposure; b) socioeconomic
factors and occupational exposures, including disruption of the
circadian rhythm through shift work; c)  lifestyle factors, smok-
ing, nutrition, obesity and physical activity; d) medical history and
consumption of specific drugs; e) hormonal factors, including expo-
sures in early stages of life; f) infectious agents; and g) family
history of cancer and genetic variation. Main effects and interac-
tions, specifically with genetic factors, will be analyzed together
with an evaluation by tumour subphenotypes.
METHODS
Study design
MCC-Spain is  a  population-based multicase-control study car-
ried out between September 2008 and December 2013 in  12
Spanish provinces (Asturias, Barcelona, Cantabria, Girona, Granada,
Gipuzkoa, Huelva, León, Madrid, Murcia, Navarra and Valencia).
Recruitment of cases and controls was performed simultaneously:
study personnel contacted newly diagnosed cancer cases in the
23 collaborating hospitals, and invited through the telephone
population controls, who had been randomly selected from the
administrative records of selected primary care health centres
located within these hospitals’ catchment area. In total, the study
recruited 10,183 subjects (Table 1).  All participants had to be 20-85
years, to have resided in  the catchment area for at least 6 months
prior to recruitment, and to be able to answer the epidemiological
questionnaire. Each province recruited cases of at least two differ-
ent tumour sites. Cases were identified, as soon as possible after the
diagnosis was made, through active search that included periodical
visits to  the collaborating hospital departments (i.e. gynaecology,
urology, gastroenterology, oncology, general surgery, radiotherapy,
and pathology departments). We included histologically confirmed
incident cases of cancer of the prostate (International Classifica-
tion of Diseases 10th Revision [ICD-10]: C61, D07.5), breast (C50,
D05.1, D05.7), colon or rectum (C18, C19, C20, D01.0, D01.1, D01.2),
stomach (C16, D00.2), lower third of the oesophagus (C15.5), or
chronic lymphocytic leukaemia and small lymphocytic lymphoma
(C91.1), with no prior history of the disease, and diagnosed within
the recruitment period, which differed by province; in  CLL preva-
lent cases were also recruited. Controls were frequency-matched
to  cases, by age, sex and region, ensuring that in each region there
was at least one control of the same sex and 5-year interval for each
case. For each control needed, a  total of five potential participants of
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Table 1
Number of cases and controls with complete interviews by tumour type and geographic area.
Area (number of hospitals) Controls Colorectal Breast Prostate Stomach/Oesophagus CLL  Total Start (month/year) Finish (month/year)
Asturias (2) 232 77 70 16 15 53 463 11/08 2/12
Barcelona (4) 1,037 702 292 405 107 402 2,945 9/07 12/13
Cantabria (1) 378 151 142 175 26 22 894 4/10 7/12
Girona  (2) 82  47  30 159 3/12 7/13
Granada  (2) 187 166 65 5 47 470 4/10 6/13
Gipuzkoa (2) 362 119 226 707 2/08 7/10
Huelva  (2) 178 74 115 52 16 435 4/10 5/13
León  (1) 441 406 228 127 1,202 2/09 6/12
Madrid  (2) 733 233 342 315 121 1,744 12/08 5/12
Murcia  (1) 42  36 2 80 1/08 6/10
Navarra (2) 274 125 227 59 685 10/08 3/11
Valencia  (2) 155 82 61  87 14 399 7/10 4/12
TOTAL  4,101 2,171 1,750 1,115 492 554 10,183 9/07 12/13
similar age, sex and hospital catchment area were randomly
selected from the general practitioner lists. If contact with the first
person of this list was not possible after a minimum of five tries at
different times of the day, or if he/she refused to participate, the
following person of the list was approached.
In Table 2 we present the main characteristics of the study pop-
ulation.
Response rates
Response rates were calculated using subjects interviewed
in the numerator, and all subjects including refusals in  the
denominator.13,14 For cases, these response rates were 68% for colo-
rectal cancer cases, 71% for breast, 72% for prostate, 57% for gastric
and 87% for CLL. In controls, mean participation rate of controls was
53% and varied by region. For 22% of the subjects the phone contact
was not possible due wrong phone number or  no-answer.
Questionnaires, biological samples, hospital records and
anthropometric measurements
A structured computerized epidemiological questionnaire was
administered by  trained personnel in  a  face-to-face interview
(http://www.mccspain.org). The average duration of the inter-
view was 70 minutes (range 30-130). Information was  collected
on socio-demographic factors, residential history, lifelong retro-
spective environmental exposures, including water consumption
and use (showering, bathing, swimming in  pools), occupational his-
tory -including night shift-, medication, lifestyles–smoking, alcohol
consumption, physical activity, use of cosmetic products-, sun-
bathing and sleeping habits, personal/family medical history and
quality of the interview. Missing values on key variables and spe-
cific questions on additional study objectives (e.g. questions on
disruption of the circadian rhythm) were completed through sub-
sequent telephone contact. The main characteristics of the study
population are presented in Table 2.  After the interview, biolog-
ical samples and anthropometric data were obtained following
the study protocol. Height and weight at different ages were self-
reported and waist and hip circumference were measured with a
tape. Subjects were provided a semi-quantitative Food Frequency
Questionnaire (FFQ), which was a  modified version from a previ-
ously validated instrument in  Spain15 to include regional products.
It included 140 food items, and assessed usual dietary intake dur-
ing the previous year. Portion sizes were specified for each item,
and photographs were used to define degrees of doneness. Infor-
mation on consumption of vitamin and mineral supplements and
on important changes on dietary habits in  the past 5 years were
also collected. The FFQ was self-administered and returned by mail
or filled out face to face (global response rate 88%).
When feasible, 27 ml of peripheral blood was drawn from par-
ticipants, which were aliquoted in  whole blood, plasma, cellular
fraction for DNA extraction, and serum and stored at -80 ◦C. Saliva
was collected for subjects refusing to donate blood and for all CLL
cases, with the Oragene® DNA Kit and stored at room temper-
ature until DNA extraction. We  collected biological samples for
DNA extraction for 96% of participants with interview (76% blood
and 27% saliva) as well as toenail and hair samples were taken
from participants (79% and 84% respectively). In 4 centres (Madrid,
Cantabria, Asturias and Huelva, which include approximately 1/3
of the study participants) cases and controls also donated urine
samples (60 ml)  that  were aliquoted and frozen at -80 ◦C. Fresh
tumour biopsies or paraffin embedded samples are available in all
participating hospitals.
Standardised basic clinical and pathological information on the
diagnosis and treatment of tumours was collected from hospital
records using a predefined format.
Sociodemographic, lifestyle and environmental factors
MCC-Spain will examine the Socioeconomic status will be
examined using multilevel approaches that allow the evaluation of
the role of structural socioeconomic factors on health. Environmen-
tal justice, proximity to  green spaces and environmental pollution
will be assessed through an evaluation of exposures proximate to
the place of residence.
Lifestyle exposures are one of the main objectives of  this study.
Diet is examined through summary intakes of relevant food  groups
based on reported intake frequencies and portion size information.
Food composition tables were developed and will be combined
with reported intake frequencies and cooking method preferences
to estimate intakes of nutrients, food contaminants (e.g. polycyclic
aromatic hydrocarbons) and food properties (e.g. total antioxidant
capacity. An a  priori Mediterranean diet score, alternative diet pat-
terns and a  factor-analysis derived diet pattern will be examined.
General and central obesity is examined together with leisure time
physical activity and sedentary lifestyle. Numerous other potential
risk factors that  could be associated with the cancers investigated
are examined. These include, among others, smoking habits, expo-
sure to medical radiation, use of cosmetics, use of tight clothes and
belts, exposure to sun or  sleeping patterns.
Use of medical drugs was  collected through personal inter-
views, mainly by indication. Information was coded (Anatomical
Therapeutic Chemical-ATC code) to assess individual exposure
to different drugs including statins and anti-inflammatory drugs,
analgesics, hormones, antihypertensives, beta-blockers, bisphos-
phonates and corticosteroids.
Hormonal factors and endocrine disruption are  also exam-
ined. Sex dimorphic phenotypes (finger ratio and anogenital
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Table  2
Main characteristics of the population of the MCC-Spain study.
Controls Colorectal Breast Prostate Stomach/Oesophagus CLL
N  = 4101 N = 2171 N =  1750 N = 1115 N = 492 N =  554
Area
Asturias 232 (5.7%) 77  (3.5%) 70 (4%) 16  (1.4%) 15 (3%) 53  (9.6%)
Barcelona 1037  (25.3%) 702 (32.3%) 292 (16.7%) 405 (36.3%) 107 (21.7%) 402 (72.6%)
Cantabria 378 (9.2%) 151 (7%) 142 (8.1%) 175 (15.7%) 26 (5.3%) 22  (4%)
Girona  82  (2%) 47 (2.7%) 30 (5.4%)
Granada 187 (4.6%) 166 (7.6%) 65  (5.8%) 5 (1%) 47  (8.5%)
Gipuzkoa 362 (8.8%) 119 (5.5%) 226 (12.9%)
Huelva 178 (4.3%) 74  (3.4%) 115 (6.6%) 52  (4.7%) 16 (3.3%)
León  441 (10.8%) 406 (18.7%) 228 (13%) 127 (25.8%)
Madrid 733 (17.9%) 233 (10.7%) 342 (19.5%) 315 (28.3%) 121 (24.6%)
Murcia 42  (1%) 36  (1.7%) 2 (0.4%)
Navarra 274 (6.7%) 125 (5.8%) 227 (13%) 59 (12%)
Valencia 155 (3.8%) 82 (3.8%) 61 (3.5%) 87 (7.8%) 14 (2.8%)
Sex
Men  2063  (50.3%) 1387 (63.9%) 1115 (100%) 336 (68.3%) 334 (60.3%)
Women  2038  (49.7%) 784 (36.1%) 1750 (100%) 156 (31.7%) 220 (39.7%)
Age,  mean(sd) 62.9 (12.1) 67.0 (10.8) 56.4 (12.6) 66.1 (7.33) 66.2 (12.3) 66.1 (10.3)
Education
Less  than primary school 753 (18.4%) 696 (32.1%) 271 (15.5%) 261 (23.4%) 147 (29.9%) 147 (26.5%)
Primary school 1307  (31.9%) 822 (37.9%) 567 (32.4%) 441 (39.6%) 186 (37.8%) 160 (28.9%)
Secondary school 1182 (28.8%) 429 (19.8%) 579 (33.1%) 242 (21.7%) 106 (21.5%) 149 (26.9%)
University 859 (20.9%) 224 (10.3%) 333 (19.0%) 171 (15.3%) 53 (10.8%) 98  (17.7%)
Race
White 4034  (98.4%) 2147 (98.9%) 1703 (97.3%) 1099 (98.6%) 474 (96.3%) 549 (99.1%)
Non-white 67  (1.63%) 24  (1.11%) 47 (2.69%) 16  (1.43%) 18 (3.66%) 5 (0.90%)
CLL: lymphocytic leukaemia.
distance) will be evaluated in  relation to the development of breast
and  prostate cancer. The ratio of the length of the index finger
and middle finger of both hands (2D: 4D) were measured using
callipers with a  resolution of 0.05 mm,16 a validation study has
shown a good repeatability of finger measurements.17 Anogeni-
tal distance was assessed in a subgroup of prostate cancer cases
and controls.18 The influence of reproductive history, hormonal
treatments (contraceptives, hormone replacement therapy) and
influence of hormonal development (pattern of fat  distribution at
different ages, and height) will be examined. Endocrine disrupt-
ors (xenoestrogens and other persistent organic pollutants) will be
measured in serum through a  determination of the global xenoe-
strogenic burden (TEXB).19
Among environmental pollutants,  evaluation of drinking
water contaminants focuses on disinfection by  products (such
as trihalomethanes and haloacetic acids), nitrates and metals.
Exposure data from water companies and municipalities, national
surveillance data and new water analyses has been gathered.20,21
and modelled to  estimate historical levels of pollutants in  drinking
water and combined with individual data from the questionnaire.
Urinary trichloroacetic acid was measured in  a  subset of controls.
MCC-Spain will also study environmental exposure to different
metals, including Cd, Ni, Cr, As, Pb, Se, and Zn in relation to the five
combining biomarker-based estimations with information based
on the epidemiological information.
Occupational exposures will also be studied. All jobs con-
ducted for more than one year were recorded with information
regarding specific tasks, exposures and timing of the job. Jobs
were coded by two experts following the Spanish National Clas-
sification of Occupations (CNO-94). The Spanish JEM, MatEmEsp,
will be applied.22 Detailed information on work shift (rotating
and night) and disruption of the circadian rhythm was also
collected.
Other possible etiological factors have also been included in the
project. Among them, several infections will be evaluated in rela-
tion to colorectal and gastric tumours and CLL. The role of H. pylori
infection will be estimated using seroprevalence against several
virulence antigens. In relation to CLL, seroprevalence of  several
polyomaviruses, herpesviruses, and Chlamydia trachomatis will be
evaluated. Additionally the antibody response pattern to EBV will
also be measured.
Extensive information on family history was  collected to
identify familial cases. This information will allow describing
the typical family structure of study participants and, if genetic
effects are  identified, estimating their penetrance using Kin-
cohort methods. In addition, genetic analyses will be carried
out within MCC-Spain and also through participation in  interna-
tional consortia such as the prostate cancer consortium PRACTICAL
(http://ccge.medschl.cam.ac.uk/consortia/practical/). The Infinium
HumanExome BeadChip from Illumina was used to genotype
>200,000 coding markers plus 6,000 additional custom variants on
the pathways of interest such as inflammation, circadian rhythm
or detoxification.
Ethics and availability of data
The protocol of MCC-Spain was  approved by the Ethics commit-
tees of the participating institutions. All participants were informed
about the study objectives and signed an informed consent. Con-
fidentiality of data is  secured removing personal identifiers in the
datasets. The database was registered in  the Spanish Agency for
Data Protection, number 2102672171. Permission to use the study
database will be granted to  researchers outside the study group,
after revision and approval of each request by the Steering Com-
mittee. More details on the organization of the project can be found
online at http://www.mccspain.org.
DISCUSSION
Cancer locations and hypotheses examined in MCC-Spain were
selected with a  public health perspective to  provide information
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useful for cancer prevention. MCC-Spain also aims to  foster a  net-
work of research in cancer epidemiology in  Spain.
The option of a  single set of population controls and a single
questionnaire for all tumours has the main benefit of the optimiza-
tion of the economic resources. This approach has been successfully
used previously. 23 On the other hand, the main drawback is the
need to use the same tools to gather the information regarding risk
factors for all types of cases.
The advantages and problems of the selection of population
versus hospital controls have been extensively discussed.24,25 The
evaluation of a variety of exposures makes hospital controls less
suitable given the potential association between multiple diseases
and exposures of interest. As expected from other population-
based studies, participation rates of cases were higher than those
of controls. Selecting controls through lists of general practitioners
provides a representative sampling frame given the almost univer-
sal public coverage of the national health system in Spain. However,
errors in these lists concerning personal data resulted in  a  lower
than expected response rate.14
The study is population-based since we intended to  recruit all
cases with a first diagnosis of the studied tumors in the selected
health areas, using for this purpose the reference hospital/hospitals
in each area and identifying every new diagnosis of the studied can-
cers. We  could not use population cancer registries to  ascertain the
number of cases lost since in  most of the regions included in the
study there was not any such registry, but we  can certainly assume
to be few. Potential misclassification of exposure is  a major limita-
tion of case-control studies. The implementation of a computerized
questionnaire, training and continuous feedback to  interviewers,
and repeated interviews to complete missing values is likely to
reduce errors.
A challenge of current cancer epidemiology research is to accu-
rately define the molecular phenotype of tumours so that specific
risk factors can be identified for each molecular subtype. All
tumours have pathology slides in the reference hospitals that can
be retrieved and some hospitals also have tumour banks that have
collected fresh tumour tissue for some cases.
Finally, networking is  among the major achievements of the
study. MCC-Spain includes 17 different centres and has followed
organizational procedures to promote the exchange of knowledge
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